

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jinhai Medical Technology Limited

今海醫療科技股份有限公司

(Incorporated in the Cayman Islands with members' limited liability)

(Stock Code: 2225)

VOLUNTARY ANNOUNCEMENT – BUSINESS UPDATE

This announcement is made by Jinhai Medical Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide its shareholders and potential investors with the updates on the recent development of the business of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, Shanghai Jinhai Medical Technology Company Limited* (上海今海醫療科技有限公司) (“**Jinhai Medical**”), an indirect wholly-owned subsidiary of the Company, is in active preparation for the attendance of the Eighth China International Import Expo (第八屆中國國際進口博覽會) (“**CIIE**”) to be held from 5 to 10 November 2025 in Shanghai, China (the “**PRC**”). During the Eighth CIIE, Jinhai Medical and Medtronic China Orthopedics and Neurosurgery Business Group (美敦力中國骨科與神外業務集團) (“**Medtronic China**”) will jointly launch newly developed navigated spinal endoscope technique, which is expected to be applicable to spine surgery. The technique is expected to open up a new pathway for the precision and intelligent development of spinal surgery, help shorten the learning curve for clinicians in spinal endoscopic techniques, and facilitate more efficient and broader clinical application in the future.

INFORMATION OF MEDTRONIC CHINA

Medtronic China is a business unit established by Medtronic plc (“**Medtronic**”), a public limited company incorporated in the Republic of Ireland with its shares listed on the New York Stock Exchange (stock code: MDT). Medtronic is a leading global healthcare technology company with its business operations in over 150 countries and regions with over 350 office locations and over 90,000 employees.

Medtronic’s principal businesses include developing, manufacturing, distributing and selling device-based medical therapies and services for cardiovascular, neuroscience, medical surgery and diabetes. Medtronic has established its manufacturing bases in Shanghai, Changzhou, and Chengdu, the PRC. Medtronic has attended the CIIE for seven consecutive years since the first CIIE in 2018, showcasing and accelerating the adoption of its latest innovative medical technologies and products through the strong influence of the CIIE.

To the best of the Directors’ knowledge, information and belief and having made all reasonable enquiries, Medtronic is an independent third party independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”)).

INFORMATION OF THE COMPANY AND JINHAI MEDICAL

The Company is incorporated in Cayman Islands with limited liability and its Shares are listed on the Main Board of the Stock Exchange. The Company is an investment holding company and the principal activities of its operating subsidiaries are provision of manpower outsourcing and ancillary services, provision of dormitory services, and provision of IT services and construction ancillary services for the building and construction industry and provision of minimally invasive surgery solution and medical products and related services.

Jinhai Medical, an indirect wholly-owned subsidiary of the Company, is a company established in the PRC with limited liability and is principally engaged in the business of endoscope products.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jinhai Medical Technology Limited
Chen Guobao
Chairman of the Board and executive Director

Hong Kong, 15 October 2025

As at the date of this announcement, the Board comprises eight Directors, of which three are executive Directors, namely Mr. Chen Guobao, Mr. Wang Zhenfei and Mr. Li Yunping; two are non-executive Directors, namely Mr. Jiang Jiangyu and Mr. Wang Huasheng; and three are independent non-executive Directors, namely Mr. Yan Jianjun, Mr. Fan Yimin and Ms. Yang Meihua.

* *For identification purposes only*